Efficacy of BsAb therapy and outcomes
| Parameters/time point of relapse/progression after CAR-Ts . | All patients . | Early relapse . | Int relapse . | Late relapse . | P value . |
|---|---|---|---|---|---|
| Median time to best response (range), d (available for 90/92 cases) | 54 (6-337) | 45 (6-127) | 53 (14-195) | 62 (20-337) | .071 |
| Best response under BsAb, n (%) | |||||
| ORR (CR and PR) | 39 (43) | 14 (29) | 13 (54) | 12 (60) | <.001 |
| CR | 20 (22) | 5 (10) | 6 (25) | 9 (45) | .006 |
| PR | 19 (21) | 9 (19) | 7 (29) | 3 (15) | .459 |
| SD | 10 (11) | 5 (10) | 4 (17) | 1 (5) | .460 |
| PD | 43 (46) | 29 (60) | 7 (29) | 7 (35) | .021 |
| Relapse/PD rate after initiation of BsAb, n (%) | 62 (67) | 38 (79) | 15 (63) | 9 (45) | .020 |
| Median time to relapse/PD after first BsAb administration (range), mo (available for 62/62 R/R cases) | 2.1 (0.2-10.5) | 1.8 (0.2-7.6) | 2.8 (0.5-6.7) | 2.1 (0.7-10.5) | .142 |
| Reason for ending BsAb, n (%) | |||||
| PD | 62 (67) | 38 (80) | 15 (63) | 9 (45) | .020 |
| EOT | 14 (15) | 1 (2) | 6 (25) | 7 (35) | .001 |
| Death due to nonlymphoma reason | 2 (2) | 1 (2) | 1 (4) | 0 (0) | .639 |
| Consolidation of PR by allo-SCT | 6 (7) | 3 (6) | 0 (0) | 3 (15) | .136 |
| Ongoing | 8 (9) | 5 (10) | 2 (8) | 1 (5) | .768 |
| Infection | 2 (2) | 1 (2) | 1 (4) | 0 (0) | .639 |
| Median time follow-up from BsAb initiation (range), mo | 4.2 (0.3-35.3) | 3.4 (0.3-13.7) | 6 (0.7-34.4) | 8.7 (2.1-35.3) | .002 |
| Remission status at last follow-up (available for 91/92 cases), n (%) | |||||
| CR | 19 (21) | 3 (6) | 6 (25) | 10 (53) | .001 |
| PR | 8 (9) | 5 (10) | 2 (8) | 1 (5) | .795 |
| SD | 6 (7) | 4 (8) | 2 (8) | 0 (0) | .428 |
| R/R dz | 58 (64) | 36 (75) | 14 (58) | 8 (42) | .034 |
| Survival status at last follow-up, n (%) | |||||
| Alive | 44 (48) | 17 (35) | 11 (46) | 16 (80) | .004 |
| Dead | 48 (52) | 31 (65) | 13 (54) | 4 (20) | |
| Cause of death, n (%) | |||||
| R/R lymphoma | 46 (50) | 30 (63) | 12 (50) | 4 (20) | .006 |
| Nonlymphoma reasons | 2 (2) | 1 (2) | 1 (4) | 0 (0) | .639 |
| Infection | 2 (2) | 1 (2) | 1 (4) | 0 (0) | .639 |
| Parameters/time point of relapse/progression after CAR-Ts . | All patients . | Early relapse . | Int relapse . | Late relapse . | P value . |
|---|---|---|---|---|---|
| Median time to best response (range), d (available for 90/92 cases) | 54 (6-337) | 45 (6-127) | 53 (14-195) | 62 (20-337) | .071 |
| Best response under BsAb, n (%) | |||||
| ORR (CR and PR) | 39 (43) | 14 (29) | 13 (54) | 12 (60) | <.001 |
| CR | 20 (22) | 5 (10) | 6 (25) | 9 (45) | .006 |
| PR | 19 (21) | 9 (19) | 7 (29) | 3 (15) | .459 |
| SD | 10 (11) | 5 (10) | 4 (17) | 1 (5) | .460 |
| PD | 43 (46) | 29 (60) | 7 (29) | 7 (35) | .021 |
| Relapse/PD rate after initiation of BsAb, n (%) | 62 (67) | 38 (79) | 15 (63) | 9 (45) | .020 |
| Median time to relapse/PD after first BsAb administration (range), mo (available for 62/62 R/R cases) | 2.1 (0.2-10.5) | 1.8 (0.2-7.6) | 2.8 (0.5-6.7) | 2.1 (0.7-10.5) | .142 |
| Reason for ending BsAb, n (%) | |||||
| PD | 62 (67) | 38 (80) | 15 (63) | 9 (45) | .020 |
| EOT | 14 (15) | 1 (2) | 6 (25) | 7 (35) | .001 |
| Death due to nonlymphoma reason | 2 (2) | 1 (2) | 1 (4) | 0 (0) | .639 |
| Consolidation of PR by allo-SCT | 6 (7) | 3 (6) | 0 (0) | 3 (15) | .136 |
| Ongoing | 8 (9) | 5 (10) | 2 (8) | 1 (5) | .768 |
| Infection | 2 (2) | 1 (2) | 1 (4) | 0 (0) | .639 |
| Median time follow-up from BsAb initiation (range), mo | 4.2 (0.3-35.3) | 3.4 (0.3-13.7) | 6 (0.7-34.4) | 8.7 (2.1-35.3) | .002 |
| Remission status at last follow-up (available for 91/92 cases), n (%) | |||||
| CR | 19 (21) | 3 (6) | 6 (25) | 10 (53) | .001 |
| PR | 8 (9) | 5 (10) | 2 (8) | 1 (5) | .795 |
| SD | 6 (7) | 4 (8) | 2 (8) | 0 (0) | .428 |
| R/R dz | 58 (64) | 36 (75) | 14 (58) | 8 (42) | .034 |
| Survival status at last follow-up, n (%) | |||||
| Alive | 44 (48) | 17 (35) | 11 (46) | 16 (80) | .004 |
| Dead | 48 (52) | 31 (65) | 13 (54) | 4 (20) | |
| Cause of death, n (%) | |||||
| R/R lymphoma | 46 (50) | 30 (63) | 12 (50) | 4 (20) | .006 |
| Nonlymphoma reasons | 2 (2) | 1 (2) | 1 (4) | 0 (0) | .639 |
| Infection | 2 (2) | 1 (2) | 1 (4) | 0 (0) | .639 |
allo-SCT, allogeneic SCT; CR, complete remission; EOT, end of treatment; PR, partial remission.